000889730 001__ 889730
000889730 005__ 20220223143403.0
000889730 0247_ $$2doi$$a10.1016/j.ejps.2020.105581
000889730 0247_ $$2ISSN$$a0928-0987
000889730 0247_ $$2ISSN$$a1879-0720
000889730 0247_ $$2Handle$$a2128/26810
000889730 0247_ $$2altmetric$$aaltmetric:92531982
000889730 0247_ $$2pmid$$a33035662
000889730 0247_ $$2WOS$$aWOS:000597224100001
000889730 037__ $$aFZJ-2021-00351
000889730 082__ $$a610
000889730 1001_ $$0P:(DE-Juel1)164354$$aElfgen, Anne$$b0$$ufzj
000889730 245__ $$aOral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid
000889730 260__ $$aNew York, NY [u.a.]$$bElsevier$$c2021
000889730 3367_ $$2DRIVER$$aarticle
000889730 3367_ $$2DataCite$$aOutput Types/Journal article
000889730 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1645604851_22416
000889730 3367_ $$2BibTeX$$aARTICLE
000889730 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000889730 3367_ $$00$$2EndNote$$aJournal Article
000889730 520__ $$aAmyloid-β (Aβ) plays a central role in the development and progression of Alzheimer's disease (AD) with Aβ oligomers representing the most toxic species. The all-d-enantiomeric peptide RD2, which recently successfully completed clinical phase I, specifically eliminates Aβ oligomers in vitro as well as in vivo and improves cognitive deficits in various transgenic AD mouse models even after oral administration. To further enhance the oral absorption of RD2, folic acid has been conjugated to the d-peptide promoting an endocytosis-mediated uptake via a folate receptor located in the intestine. Two different conjugation strategies were selected to obtain prodrugs with folic acid being cleaved after intestinal absorption releasing unmodified RD2 in order to enable RD2's unaltered systemic efficacy. Both conjugates remained stable in simulated gastrointestinal fluids. But only one of them was suitable as prodrug as it was cleaved to RD2 in vitro in human blood plasma and liver microsomes and in vivo in mice after intravenous injection leading to a systemic release of RD2. Furthermore, the conjugate's permeability in vitro and after oral administration in mice was strongly enhanced compared to unconjugated RD2 demonstrating the prodrug's functionality. However, the conjugate seemed to have impaired the mice's wellbeing shortly after oral administration possibly resulting from strain-specific hypersensitivity to folic acid. Nevertheless, we assume that the prodrug is actually non-toxic, especially in lower concentrations as verified by a cell viability test. Furthermore, lower dosages can be applied with unaltered efficacy due to its enhanced oral absorption.
000889730 536__ $$0G:(DE-HGF)POF4-5244$$a5244 - Information Processing in Neuronal Networks (POF4-524)$$cPOF4-524$$fPOF IV$$x0
000889730 588__ $$aDataset connected to CrossRef
000889730 7001_ $$0P:(DE-Juel1)133853$$aSantiago-Schübel, Beatrix$$b1$$ufzj
000889730 7001_ $$0P:(DE-Juel1)142389$$aHupert, Michelle$$b2$$ufzj
000889730 7001_ $$0P:(DE-Juel1)165908$$aSchemmert, Sarah$$b3$$ufzj
000889730 7001_ $$0P:(DE-Juel1)166069$$aSchartmann, Elena$$b4
000889730 7001_ $$0P:(DE-Juel1)131709$$aTusche, Markus$$b5$$ufzj
000889730 7001_ $$0P:(DE-Juel1)171922$$aGering, Ian$$b6
000889730 7001_ $$0P:(DE-Juel1)162137$$aZafiu, Christian$$b7$$ufzj
000889730 7001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b8$$eCorresponding author$$ufzj
000889730 773__ $$0PERI:(DE-600)1483522-8$$a10.1016/j.ejps.2020.105581$$gVol. 156, p. 105581 -$$p105581 -$$tEuropean journal of pharmaceutical sciences$$v156$$x0928-0987$$y2021
000889730 8564_ $$uhttps://juser.fz-juelich.de/record/889730/files/Oral%20absorption%20enhancement%20of%20the%20amyloid-%CE%B2%20oligomer%20eliminating%20compound%20RD2%20by%20conjugation%20with%20folic%20acid.pdf$$yPublished on 2020-10-06. Available in OpenAccess from 2021-10-06.$$zStatID:(DE-HGF)0510
000889730 909CO $$ooai:juser.fz-juelich.de:889730$$popenaire$$pVDB$$popen_access$$pdnbdelivery$$pdriver
000889730 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)164354$$aForschungszentrum Jülich$$b0$$kFZJ
000889730 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133853$$aForschungszentrum Jülich$$b1$$kFZJ
000889730 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)142389$$aForschungszentrum Jülich$$b2$$kFZJ
000889730 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)165908$$aForschungszentrum Jülich$$b3$$kFZJ
000889730 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131709$$aForschungszentrum Jülich$$b5$$kFZJ
000889730 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)171922$$aForschungszentrum Jülich$$b6$$kFZJ
000889730 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)162137$$aForschungszentrum Jülich$$b7$$kFZJ
000889730 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b8$$kFZJ
000889730 9131_ $$0G:(DE-HGF)POF4-524$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5244$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vMolecular and Cellular Information Processing$$x0
000889730 9130_ $$0G:(DE-HGF)POF3-553$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vPhysical Basis of Diseases$$x0
000889730 9141_ $$y2021
000889730 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-22
000889730 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-22
000889730 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-08-22
000889730 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-22
000889730 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-08-22
000889730 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000889730 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
000889730 915__ $$0StatID:(DE-HGF)1200$$2StatID$$aDBCoverage$$bChemical Reactions$$d2020-08-22
000889730 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-08-22
000889730 915__ $$0StatID:(DE-HGF)1210$$2StatID$$aDBCoverage$$bIndex Chemicus$$d2020-08-22
000889730 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-22
000889730 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-22
000889730 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-08-22
000889730 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-08-22
000889730 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J PHARM SCI : 2018$$d2020-08-22
000889730 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-22
000889730 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-08-22$$wger
000889730 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-22
000889730 920__ $$lyes
000889730 9201_ $$0I:(DE-Juel1)IBI-7-20200312$$kIBI-7$$lStrukturbiochemie$$x0
000889730 9201_ $$0I:(DE-Juel1)ZEA-3-20090406$$kZEA-3$$lAnalytik$$x1
000889730 980__ $$ajournal
000889730 980__ $$aVDB
000889730 980__ $$aI:(DE-Juel1)IBI-7-20200312
000889730 980__ $$aI:(DE-Juel1)ZEA-3-20090406
000889730 980__ $$aUNRESTRICTED
000889730 9801_ $$aFullTexts